Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1

Conditions

Multiple Myeloma 427Neoplasms, Plasma Cell 68Lymphoma, Mantle-Cell 66Lymphoma 65Recurrence 64Lymphoma, Non-Hodgkin 43Lymphoma, Follicular 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Leukemia, Myeloid, Acute 36Lymphoma, Large B-Cell, Diffuse 34Waldenstrom Macroglobulinemia 33Lymphoma, B-Cell, Marginal Zone 30Leukemia, Lymphocytic, Chronic, B-Cell 28Neoplasms 24Carcinoma, Non-Small-Cell Lung 24Immunoglobulin Light-chain Amyloidosis 23Leukemia 21Hodgkin Disease 17Lymphoma, B-Cell 14Burkitt Lymphoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Myelodysplastic Syndromes 13Lymphoma, Large-Cell, Anaplastic 13Hematologic Neoplasms 13Immunoblastic Lymphadenopathy 12Breast Neoplasms 12Mycosis Fungoides 11Lymphoma, T-Cell, Cutaneous 11Lymphoma, Large-Cell, Immunoblastic 11Congenital Abnormalities 11

Interventions

Dexamethasone 8Lenalidomide 4dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3auricularum 3Calcium Dobesilate 3Bortezomib 3pomalidomide 2ixazomib 2filanesib 2Steroids 2Radiotherapy 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2silmitasertib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1milatuzumab 1cc-486 1carfilzomib 1Thalidomide 1Specimen Handling 1Sodium Selenite 1Radiation 1Proteasome Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Plasmacytoma × Bortezomib × Clear all
NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Phase 3 Completed
498 enrolled 15 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT00569868 2011-08-12

UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

University of Arkansas

Phase NA Completed
11 enrolled 4 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡